
KTTA Stock Forecast & Price Target
KTTA Analyst Ratings
Bulls say
Pasithea Therapeutics is a biotechnology company with a promising pipeline focused on the discovery and development of treatments for central nervous system disorders and other diseases. The recent protocol amendment for its Phase 1/1b trial of PAS-004 in NF1 patients allows for a more comprehensive evaluation of the drug's efficacy, potentially de-risking its future development. The company's strategic plans for their lead asset, PAS-004, in both NF1 and oncology markets, as well as the recent RPDD and PRV granted by the FDA, present significant upside value potential for investors, despite being in the early stages of clinical development. Overall, Pasithea Therapeutics has strong potential to become a key player in the biotechnology industry.
Bears say
Pasithea Therapeutics is currently overvalued as the market has not fully accounted for the potential risks associated with their advanced cancer study and the unmet medical need for their PAS-004 drug for Neurofibromatosis Type 1. The company's current market model for PAS-004 is conservative and may not accurately depict the commercial potential of the drug. Furthermore, the company has limited revenue streams, with only one reportable segment, which could make it vulnerable to market volatility.
This aggregate rating is based on analysts' research of Pasithea Therapeutics Corp and is not a guaranteed prediction by Public.com or investment advice.
KTTA Analyst Forecast & Price Prediction
Start investing in KTTA
Order type
Buy in
Order amount
Est. shares
0 shares